SG11202111387YA - Oligonucleotide compositions and methods of use thereof - Google Patents

Oligonucleotide compositions and methods of use thereof

Info

Publication number
SG11202111387YA
SG11202111387YA SG11202111387YA SG11202111387YA SG11202111387YA SG 11202111387Y A SG11202111387Y A SG 11202111387YA SG 11202111387Y A SG11202111387Y A SG 11202111387YA SG 11202111387Y A SG11202111387Y A SG 11202111387YA SG 11202111387Y A SG11202111387Y A SG 11202111387YA
Authority
SG
Singapore
Prior art keywords
methods
oligonucleotide compositions
oligonucleotide
compositions
Prior art date
Application number
SG11202111387YA
Inventor
Michael John Byrne
Vinod Vathipadiekal
Naoki Iwamoto
Chandra Vargeese
Lankai Guo
Andrew Guzior Hoss
Original Assignee
Wave Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wave Life Sciences Ltd filed Critical Wave Life Sciences Ltd
Publication of SG11202111387YA publication Critical patent/SG11202111387YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
SG11202111387YA 2019-04-25 2020-04-24 Oligonucleotide compositions and methods of use thereof SG11202111387YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962838763P 2019-04-25 2019-04-25
PCT/US2020/029959 WO2020219983A2 (en) 2019-04-25 2020-04-24 Oligonucleotide compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11202111387YA true SG11202111387YA (en) 2021-11-29

Family

ID=72941792

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111387YA SG11202111387YA (en) 2019-04-25 2020-04-24 Oligonucleotide compositions and methods of use thereof

Country Status (8)

Country Link
US (1) US20230145795A1 (en)
EP (1) EP3959318A4 (en)
AU (1) AU2020262485A1 (en)
BR (1) BR112021021214A2 (en)
CA (1) CA3137741A1 (en)
MX (1) MX2021012981A (en)
SG (1) SG11202111387YA (en)
WO (1) WO2020219983A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2872485B1 (en) 2012-07-13 2020-12-16 Wave Life Sciences Ltd. Asymmetric auxiliary group
KR102213609B1 (en) 2012-07-13 2021-02-08 웨이브 라이프 사이언시스 리미티드 Chiral control
MA43072A (en) 2015-07-22 2018-05-30 Wave Life Sciences Ltd COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
WO2017160741A1 (en) 2016-03-13 2017-09-21 Wave Life Sciences Ltd. Compositions and methods for phosphoramidite and oligonucleotide synthesis
JP7296882B2 (en) 2016-11-23 2023-06-23 ウェイブ ライフ サイエンシズ リミテッド Compositions and methods for phosphoramidite and oligonucleotide synthesis
CN111050806A (en) 2017-06-02 2020-04-21 波涛生命科学有限公司 Oligonucleotide compositions and methods of use thereof
WO2018223081A1 (en) 2017-06-02 2018-12-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
WO2018237194A1 (en) 2017-06-21 2018-12-27 Wave Life Sciences Ltd. Compounds, compositions and methods for synthesis
EP3664816A4 (en) 2017-08-08 2021-05-19 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
CN111108096A (en) 2017-09-18 2020-05-05 波涛生命科学有限公司 Oligonucleotide preparation technology
SG11202001783YA (en) 2017-10-12 2020-03-30 Wave Life Sciences Ltd Oligonucleotide compositions and methods thereof
US11332733B2 (en) 2018-02-12 2022-05-17 lonis Pharmaceuticals, Inc. Modified compounds and uses thereof
WO2023075766A1 (en) * 2021-10-27 2023-05-04 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
WO2023076352A2 (en) * 2021-10-27 2023-05-04 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
WO2023152371A1 (en) 2022-02-14 2023-08-17 Proqr Therapeutics Ii B.V. Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
WO2023183556A2 (en) * 2022-03-24 2023-09-28 Amcyte Pharma, Inc. Treatment for retinal disorders
WO2024013361A1 (en) 2022-07-15 2024-01-18 Proqr Therapeutics Ii B.V. Oligonucleotides for adar-mediated rna editing and use thereof
WO2024013360A1 (en) 2022-07-15 2024-01-18 Proqr Therapeutics Ii B.V. Chemically modified oligonucleotides for adar-mediated rna editing
WO2024073705A1 (en) * 2022-09-30 2024-04-04 University Of Massachusetts Ocular delivery of oligonucleotides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10202599B2 (en) * 2011-08-11 2019-02-12 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
AU2015207773B2 (en) * 2014-01-16 2021-06-17 Wave Life Sciences Ltd. Chiral design
AU2016222546B2 (en) * 2015-02-26 2020-01-23 Ionis Pharmaceuticals, Inc. Allele specific modulators of P23H rhodopsin
MA43072A (en) * 2015-07-22 2018-05-30 Wave Life Sciences Ltd COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
CR20180233A (en) * 2015-10-09 2018-05-25 Wave Life Sciences Ltd OLIGONUCLEOTID COMPOSITIONS AND THEIR METHODS
MA45270A (en) * 2016-05-04 2017-11-09 Wave Life Sciences Ltd COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES

Also Published As

Publication number Publication date
MX2021012981A (en) 2022-01-18
CA3137741A1 (en) 2020-10-29
AU2020262485A1 (en) 2021-11-11
EP3959318A2 (en) 2022-03-02
WO2020219983A2 (en) 2020-10-29
EP3959318A4 (en) 2023-10-25
WO2020219983A3 (en) 2020-12-03
US20230145795A1 (en) 2023-05-11
BR112021021214A2 (en) 2022-01-04

Similar Documents

Publication Publication Date Title
IL291933A (en) Oligonucleotide compositions and methods of use thereof
SG11202111387YA (en) Oligonucleotide compositions and methods of use thereof
IL277889A (en) Oligonucleotide compositions and methods of use thereof
SG11202010131QA (en) Oligonucleotide compositions and methods of use thereof
EP4037695A4 (en) Oligonucleotide compositions and methods of use thereof
SG11202111386UA (en) Oligonucleotide compositions and methods of use thereof
EP3965780A4 (en) Oligonucleotide compositions and methods of use thereof
EP3630199A4 (en) Oligonucleotide compositions and methods of use thereof
EP3630788A4 (en) Oligonucleotide compositions and methods of use thereof
EP3630789A4 (en) Oligonucleotide compositions and methods of use thereof
IL284882A (en) Oligonucleotide compositions and methods thereof
GB2582482B (en) CASZ compositions and methods of use
SG11202105626TA (en) Oligonucleotide compositions and methods thereof
EP4114939A4 (en) Oligonucleotide compositions and methods thereof
GB2582100B (en) CAS12C Compositions and methods of use
ZA202100780B (en) Bismuth-thiol compositions and methods of use
IL276135A (en) Compositions and methods of use
ZA201906169B (en) Synthekine compositions and methods of use
IL288259A (en) Modified gapmer oligonucleotides and methods of use
GB202105087D0 (en) Microbial compositions and methods of use
EP4081231A4 (en) Compositions comprising microbes and methods of use and making thereof
IL285247A (en) Enhanced nitrate compositions and methods of use
SG11202011227VA (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
IL282533A (en) Oligosaccharide compositions and methods of use thereof
ZA201908276B (en) Charge-tagged nucleotides and methods of use thereof